Mechanism of action
Simvastatin belongs to semisynthetic hypolipidemic agents. Chemically, it contains a hydronaphthalene ring and is a prodrug in the form of an inactive lactone. Once inside the body, the substance undergoes hydrolysis, converting into the active $\beta$-hydroxy acid.
The primary biochemical mechanism involves the inhibition of the enzyme HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase). The drug blocks the synthesis of endogenous cholesterol in hepatocytes at an early stage—at the point of mevalonate formation (mevalonate).
For the drug's delivery into liver cells during first-pass metabolism, the membrane transporter OATP1B1 is critically important. It ensures efficient uptake of statins from the blood, which simultaneously guarantees delivery to the therapeutic target and reduces systemic concentration, preventing toxic effects (particularly myopathies).
Pharmacological effects
The blockade of cholesterol synthesis triggers a compensatory hepatic response. In response to decreased intracellular cholesterol, hepatocytes activate upregulation—increasing the density and number of LDL receptors on their membranes.
Due to the increased number of receptors, receptor-mediated endocytosis is enhanced. Low-density lipoproteins (the atherogenic fraction) are actively captured from blood plasma and taken up into cells. The net effect is a significant reduction in plasma LDL concentration.
Indications and place in therapy
The drug is prescribed for lipid profile correction and the prevention of cardiovascular complications. Simvastatin is included in standard combination therapy regimens for coronary artery disease (CAD) to prevent myocardial infarction.
In complication prevention regimens, it is combined with antiplatelet agents (acetylsalicylic acid, clopidogrel) and other lipid-lowering drugs.
Administration and dosing
The drug is available as tablets in dosages of 0.01, 0.02, 0.04, and 0.08 g.
Directions for use and doses: Orally, 0.01 g once daily. If necessary and in case of insufficient efficacy, the daily dose may be gradually increased by a physician up to 0.04 g.
Group characteristics and safety
Being a prodrug, simvastatin requires metabolic activation in the liver. The presence of transport proteins, such as OATP1B1, reduces the systemic concentration of the substance and minimizes the risks of side effects (e.g., skeletal muscle damage).
In the classification of statins by source, simvastatin, along with pravastatin, belongs to semisynthetic drugs, which are chemical derivatives of natural fungal lovastatin.
Briefly: answers to topical questions
What side effects are characteristic of statins when systemic concentration increases?
Statins are characterized by muscle tissue damage and hepatotoxicity.
- Muscle tissue damage is infrequent but presents the greatest danger; it manifests as myopathy and rhabdomyolysis.
- Hepatotoxicity is a dose-dependent effect and may be accompanied by elevated liver transaminases or occur without it.
- General reactions include dyspeptic disorders, central nervous system disturbances (insomnia, headache), and skin manifestations (erythema, rash).
Simvastatin and Lovastatin are lactone prodrugs: Lazy lactone lies around idly until the liver turns it into active acid!
Class and exam questions
Is simvastatin an active substance immediately after administration?
No, simvastatin is a prodrug in the form of an inactive lactone. The $\beta$-hydroxy acid formed from it in the body becomes the active pharmacological form.
What is the role of the OATP1B1 transporter for simvastatin?
The OATP1B1 transporter ensures the uptake of the drug from the blood into hepatocytes during first-pass metabolism, which delivers it to the target and protects the body from excessive systemic concentration.
What is the main mechanism of cholesterol-lowering by statins?
Inhibition of HMG-CoA reductase in hepatocytes, reduced mevalonate synthesis, subsequent increase in hepatic LDL receptors, and enhanced uptake of LDL from the blood.
What drugs is simvastatin combined with in CAD?
For the prevention of myocardial infarction, it is combined with antiplatelet agents (acetylsalicylic acid, clopidogrel) as part of combination therapy.
What else to study on this topic
- Comparison of the pharmacokinetics of prodrugs (lovastatin, simvastatin) and active statins (pravastatin, fluvastatin)
- The role of OATP1B1 gene polymorphism in the development of statin-induced myopathies
- The effect of CYP3A4 on simvastatin metabolism and drug interactions
- Comparative efficacy of various generations of statins in lowering LDL levels
- Pathogenetic aspects of atherosclerosis and the role of the blood lipid profile
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Simvastatin" and 5,304 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.